secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2022-03-03T23:59:59+00:00
Accession:  0001104659-22-029676
Event type: other_material
Sentiment:  positive
Materiality: 0.35
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio launches SiteGuard No Rinse Antimicrobial Solution for plastic reconstructive surgery
--------------------------------------------------------------------------------

- SiteGuard uses Next Science's XBIO Technology to deconstruct biofilm and provide over 5 hours of protection.
- TELA Bio entered exclusive distribution agreement in November 2021 to market the wash in US plastic reconstructive surgery.
- First adjunctive soft-tissue technology complementing TELA's soft-tissue preservation and restoration product portfolio.
- CEO Antony Koblish cites encouraging early test market experience and plans for nationwide expansion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465922029676/0001104659-22-029676-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465922029676/tm228184d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-029676

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer